Aptamer Sciences Inc
Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company's platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well… Read more
Aptamer Sciences Inc (291650) - Total Liabilities
Latest total liabilities as of September 2025: ₩6.00 Billion KRW
Based on the latest financial reports, Aptamer Sciences Inc (291650) has total liabilities worth ₩6.00 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aptamer Sciences Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Aptamer Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aptamer Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Aptamer Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
New Advanced Electronics Technologies Co Ltd
TWO:3465
|
Taiwan | NT$1.19 Billion |
|
Display Tech Co. Ltd
KQ:066670
|
Korea | ₩51.17 Billion |
|
Glidelogic Corp.
PINK:GDLG
|
USA | $22.13K |
|
Yoo Sung Ent
KO:002920
|
Korea | ₩103.89 Billion |
|
Sunshine Oilsands Ltd
PINK:SUNYF
|
USA | $708.92 Million |
|
African Rainbow Minerals Ltd
JSE:ARI
|
South Africa | ZAC14.20 Billion |
|
Ryde Group Ltd.
NYSE MKT:RYDE
|
USA | $5.01 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Aptamer Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aptamer Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aptamer Sciences Inc (2018–2024)
The table below shows the annual total liabilities of Aptamer Sciences Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩6.54 Billion | -61.63% |
| 2023-12-31 | ₩17.06 Billion | +3.86% |
| 2022-12-31 | ₩16.42 Billion | +812.14% |
| 2021-12-31 | ₩1.80 Billion | +2.92% |
| 2020-12-31 | ₩1.75 Billion | +26.77% |
| 2019-12-31 | ₩1.38 Billion | -95.28% |
| 2018-12-31 | ₩29.25 Billion | -- |